3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Transitional Cell
14
Urinary Bladder Neoplasms
13
Colorectal Neoplasms
10
Carcinoma, Merkel Cell
9
Breast Neoplasms
9
Carcinoma, Renal Cell
7
Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Non-Small-Cell Lung
6
Small Cell Lung Carcinoma
4
Carcinoma, Hepatocellular
4
Turcot syndrome
3
Stomach Neoplasms
3
Neuroendocrine Tumors
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Penile Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Melanoma
2
Lung Neoplasms
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Neuroendocrine
2
Uterine Cervical Neoplasms
1
Interventions
nimotuzumab
1
avelumab
1
Hydroxychloroquine
1
Gemcitabine
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pancreatic Cancer Resectable
×
avelumab
×
Clear all
NCT03344172
2020-05-14
17-134
University of Pittsburgh
Phase 2
Terminated
32 enrolled
14 charts